Source: EURLEX
Language: en
Format: md

|  |  |  |  |
| --- | --- | --- | --- |
| 2.8.2021 | EN | Official Journal of the European Union | C 310/24 |

---

Judgment of the General Court of 16 June 2021 — Fidia farmaceutici v EUIPO — Ioulia and Irene Tseti Pharmaceutical Laboratories (HYAL)

(Case T-215/20) [(1)](#ntr1-C_2021310EN.01002401-E0001)

(EU trade mark - Invalidity proceedings - EU word mark HYAL - Article 51(1)(a) of Regulation (EC) No 40/94 (now Article 59(1)(a) of Regulation (EU) 2017/1001) - Absolute ground for refusal - Article 7(1)(c) of Regulation No 40/94 (now Article 7(1)(c) of Regulation 2017/1001) - Right to be heard - Audi alteram partem rule - Obligation to state reasons - Sound administration and equal treatment - Article 165(1) of Regulation 2017/1001)

(2021/C 310/30)

Language of the case: English

Parties

Applicant: Fidia farmaceutici SpA (Abano Terme, Italy) (represented by: R. Kunz-Hallstein and H.P. Kunz-Hallstein, lawyers)

Defendant: European Union Intellectual Property Office (represented by: E. Sliwinska, V. Ruzek and H. O’Neill, acting as Agents)

Other party to the proceedings before the Board of Appeal of EUIPO, intervener before the General Court: Ioulia and Irene Tseti Pharmaceutical Laboratories SA (Athens, Greece) (represented by: C. Chrysanthis, P.-V. Chardalia and A. Vasilogamvrou, lawyers)

Re:

Action brought against the decision of the Fifth Board of Appeal of EUIPO of 24 January 2020 (Case R 613/2019-5), relating to invalidity proceedings between Ioulia and Irene Tseti Pharmaceutical Laboratories and Fidia farmaceutici.

Operative part of the judgment

The Court:

|  |  |
| --- | --- |
| 1. | Dismisses the action; |

|  |  |
| --- | --- |
| 2. | Orders Fidia farmaceutici SpA to pay the costs. |

---

---

[Top](#document1)